Literature DB >> 16461574

Rationale and parameters for medication-free research in psychosis.

Thomas H McGlashan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16461574      PMCID： PMC2632209          DOI： 10.1093/schbul/sbj045

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN： 0586-7614            Impact factor:   9.306


× No keyword cloud information.
  21 in total

1.  Early subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia.

Authors:  T P Hogan; A G Awad; M R Eastwood
Journal:  Can J Psychiatry       Date:  1985-06       Impact factor: 4.356

2.  The treatment of acute schizophrenia without drugs: an investigation of some current assumptions.

Authors:  W T Carpenter; T H McGlashan; J S Strauss
Journal:  Am J Psychiatry       Date:  1977-01       Impact factor: 18.112

Review 3.  Early detection and intervention with schizophrenia: rationale.

Authors:  T H McGlashan; J O Johannessen
Journal:  Schizophr Bull       Date:  1996       Impact factor: 9.306

4.  Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.

Authors:  M Gitlin; K Nuechterlein; K L Subotnik; J Ventura; J Mintz; D L Fogelson; G Bartzokis; M Aravagiri
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

5.  An investigation of the postpsychotic depressive syndrome.

Authors:  T H McGlashan; W T Carpenter
Journal:  Am J Psychiatry       Date:  1976-01       Impact factor: 18.112

6.  The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design.

Authors:  T H McGlashan; R B Zipursky; D Perkins; J Addington; T J Miller; S W Woods; K A Hawkins; R Hoffman; S Lindborg; M Tohen; A Breier
Journal:  Schizophr Res       Date:  2003-05-01       Impact factor: 4.939

7.  The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later.

Authors:  C M Harding; G W Brooks; T Ashikaga; J S Strauss; A Breier
Journal:  Am J Psychiatry       Date:  1987-06       Impact factor: 18.112

Review 8.  Postpsychotic depression in schizophrenia.

Authors:  T H McGlashan; W T Carpenter
Journal:  Arch Gen Psychiatry       Date:  1976-02

9.  Subjective response to antipsychotic drugs.

Authors:  T Van Putten; P R May; S R Marder; L A Wittmann
Journal:  Arch Gen Psychiatry       Date:  1981-02

Review 10.  Half a century of antipsychotics and still a central role for dopamine D2 receptors.

Authors:  Shitij Kapur; David Mamo
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2003-10       Impact factor: 5.067
View more
  3 in total

Review 1.  The Use of Continuous Treatment Versus Placebo or Intermittent Treatment Strategies in Stabilized Patients with Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with First- and Second-Generation Antipsychotics.

Authors:  Marc De Hert; Jan Sermon; Paul Geerts; Kristof Vansteelandt; Joseph Peuskens; Johan Detraux
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

Review 2.  Weighing the evidence for harm from long-term treatment with antipsychotic medications: A systematic review.

Authors:  Nancy Sohler; Ben G Adams; David M Barnes; Gregory H Cohen; Seth J Prins; Sharon Schwartz
Journal:  Am J Orthopsychiatry       Date:  2015-12-14

3.  Antipsychotic Maintenance Treatment: Time to Rethink?

Authors:  Joanna Moncrieff
Journal:  PLoS Med       Date:  2015-08-04       Impact factor: 11.069
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.